Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04476-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Ying-Hsin Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medi…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized, Bevacizumab. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science Council.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
- Liver Transplant Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan. chh4366@yahoo…
ORCID-Profile: Chao-Hung Hung
Förderung
- National Science Council
Zitieren
APA
Chen, Y. H., Li, W. F., Chen, Y. H., Tsai, M. C., Kuo, Y. H., Wang, J. H., Chen, C. H., Lu, S. N., Wang, C. C., & Hung, C. H. (2026). Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04476-y
Vancouver
Chen YH, Li WF, Chen YH, Tsai MC, Kuo YH, Wang JH, et al. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04476-y
BibTeX
@article{Chen2026,
author = {Chen, Ying-Hsin and Li, Wei-Feng and Chen, Yen-Hao and Tsai, Ming-Chao and Kuo, Yuan-Hung and Wang, Jing-Houng and Chen, Chien-Hung and Lu, Sheng-Nan and Wang, Chih-Chi and Hung, Chao-Hung},
title = {Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04476-y}
}
EUVIMED